603392 Stock Overview
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Beijing Wantai Biological Pharmacy Enterprise Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CN¥153.71|
|52 Week High||CN¥206.74|
|52 Week Low||CN¥118.54|
|1 Month Change||20.66%|
|3 Month Change||-19.54%|
|1 Year Change||-11.84%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||36.11%|
Recent News & Updates
|603392||CN Biotechs||CN Market|
Return vs Industry: 603392 exceeded the CN Biotechs industry which returned -33.8% over the past year.
Return vs Market: 603392 underperformed the CN Market which returned -10.1% over the past year.
|603392 Average Weekly Movement||7.9%|
|Biotechs Industry Average Movement||7.0%|
|Market Average Movement||7.3%|
|10% most volatile stocks in CN Market||10.2%|
|10% least volatile stocks in CN Market||5.1%|
Stable Share Price: 603392 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: 603392's weekly volatility (8%) has been stable over the past year.
About the Company
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. researches, develops, produces, distributes, and sells infectious disease diagnostic reagents and vaccines in China and internationally. The company provides COVID 19, HIV and HTLV, Hepatitis, EV-71, and Tuberculosis diagnostics test kits; Hepatitis C and Syphilis detection reagents; automated immunoassays; ELISA kits and rapid tests for infectious disease diagnostics; chemiluminescence and clinical chemistry reagents; immunodiagnostic reagents; and Hepatitis E and human papillomavirus vaccines.
Beijing Wantai Biological Pharmacy Enterprise Fundamentals Summary
|603392 fundamental statistics|
Is 603392 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|603392 income statement (TTM)|
|Cost of Revenue||CN¥1.05b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||3.48|
|Net Profit Margin||37.83%|
How did 603392 perform over the long term?See historical performance and comparison
0.09%Current Dividend Yield
Is 603392 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 603392?
Other financial metrics that can be useful for relative valuation.
|What is 603392's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 603392's PE Ratio compare to its peers?
|603392 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
300122 Chongqing Zhifei Biological Products
300142 Walvax Biotechnology
688363 Bloomage BioTechnology
002030 Daan Gene
603392 Beijing Wantai Biological Pharmacy Enterprise
Price-To-Earnings vs Peers: 603392 is good value based on its Price-To-Earnings Ratio (44.2x) compared to the peer average (70.6x).
Price to Earnings Ratio vs Industry
How does 603392's PE Ratio compare vs other companies in the CN Biotechs Industry?
Price-To-Earnings vs Industry: 603392 is expensive based on its Price-To-Earnings Ratio (44.2x) compared to the CN Biotechs industry average (39.3x)
Price to Earnings Ratio vs Fair Ratio
What is 603392's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||44.2x|
|Fair PE Ratio||42.6x|
Price-To-Earnings vs Fair Ratio: 603392 is expensive based on its Price-To-Earnings Ratio (44.2x) compared to the estimated Fair Price-To-Earnings Ratio (42.6x).
Share Price vs Fair Value
What is the Fair Price of 603392 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 603392 (CN¥153.71) is trading below our estimate of fair value (CN¥230.97)
Significantly Below Fair Value: 603392 is trading below fair value by more than 20%.
Price to Earnings Growth Ratio
PEG Ratio: 603392 is poor value based on its PEG Ratio (1.7x)
Discover undervalued companies
How is Beijing Wantai Biological Pharmacy Enterprise forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Future Growth Score6/6
Future Growth Score 6/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 603392's forecast earnings growth (26.7% per year) is above the savings rate (3.2%).
Earnings vs Market: 603392's earnings (26.7% per year) are forecast to grow faster than the CN market (23.9% per year).
High Growth Earnings: 603392's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 603392's revenue (24.1% per year) is forecast to grow faster than the CN market (17.5% per year).
High Growth Revenue: 603392's revenue (24.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 603392's Return on Equity is forecast to be very high in 3 years time (41.7%).
Discover growth companies
How has Beijing Wantai Biological Pharmacy Enterprise performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 603392 has a high level of non-cash earnings.
Growing Profit Margin: 603392's current net profit margins (37.8%) are higher than last year (31.2%).
Past Earnings Growth Analysis
Earnings Trend: 603392's earnings have grown significantly by 69.5% per year over the past 5 years.
Accelerating Growth: 603392's earnings growth over the past year (242%) exceeds its 5-year average (69.5% per year).
Earnings vs Industry: 603392 earnings growth over the past year (242%) exceeded the Biotechs industry 11.3%.
Return on Equity
High ROE: 603392's Return on Equity (53.4%) is considered outstanding.
Discover strong past performing companies
How is Beijing Wantai Biological Pharmacy Enterprise's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 603392's short term assets (CN¥6.5B) exceed its short term liabilities (CN¥3.0B).
Long Term Liabilities: 603392's short term assets (CN¥6.5B) exceed its long term liabilities (CN¥168.3M).
Debt to Equity History and Analysis
Debt Level: 603392 has more cash than its total debt.
Reducing Debt: 603392's debt to equity ratio has reduced from 5.8% to 4.9% over the past 5 years.
Debt Coverage: 603392's debt is well covered by operating cash flow (708.7%).
Interest Coverage: 603392 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Beijing Wantai Biological Pharmacy Enterprise current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 603392's dividend (0.089%) isn’t notable compared to the bottom 25% of dividend payers in the CN market (0.48%).
High Dividend: 603392's dividend (0.089%) is low compared to the top 25% of dividend payers in the CN market (1.94%).
Stability and Growth of Payments
Stable Dividend: 603392 is not paying a notable dividend for the CN market, therefore no need to check if payments are stable.
Growing Dividend: 603392 is not paying a notable dividend for the CN market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: 603392 is not paying a notable dividend for the CN market.
Cash Payout to Shareholders
Cash Flow Coverage: 603392 is not paying a notable dividend for the CN market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Zixin Qiu (58 yo)
Mr. Zixin Qiu serves as the Chairman and General Manager at Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. and serves as its Board Secretary. He has been with Beijing Wantai Biological Pharmacy En...
Experienced Board: 603392's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
- Ticker: 603392
- Exchange: XSSC
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CN¥135.297b
- Shares outstanding: 880.21m
- Website: https://www.ystwt.com
Number of Employees
- Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
- No. 31 Kexueyuan Road
- Changping District
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/30 00:00|
|End of Day Share Price||2022/06/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.